Navigation Links
Evaluate Launches Enhanced Orphan Drug Intelligence
Date:6/17/2013

LONDON and BOSTON, June 17, 2013 /PRNewswire/ --

The worldwide orphan drug market is set to reach $127 billion by 2018, accounting for nearly 16 percent of total prescription drug sales, according to the recently released Orphan Drug Report 2013 from Evaluate.  

To better serve its clients' needs in regard to this growing segment of the pharmaceutical industry, Evaluate has enhanced its EvaluatePharma core product database to include in-depth, fact-based orphan drug analysis with data fields for integrated US, EU and Japan orphan drug designations. The enhanced orphan drug content will be available to all EvaluatePharma service clients on June 20, 2013.

"As a company, we are focused on our clients' success. This enhancement allows our clients to size and track the orphan drug market in order to make more informed, strategic decisions about portfolio strategy, growth opportunities and investments," said Anthony Raeside, Head of Research at Evaluate.

EvaluatePharma has identified all products that have orphan drug designations filed in the US, EU or Japan, and has defined a clean 'orphan' sub-set of products through a fully transparent and documented methodology.

The new enhancement facilitates global analysis of the orphan drug R&D and commercial landscape - including the ability to:

  • TRACK the orphan drug market via a transparent methodology
  • MAKE orphan drug commercial assessments
  • CONDUCT competitive intelligence including patent expiries and exclusivities
  • SCREEN for orphan drug licensing opportunities by product, designation, indica
    '/>"/>

SOURCE Evaluate Ltd.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. New Subanalyses of RE-LY® Trial Evaluate PRADAXA in Subsets of Patients with Non-Valvular Atrial Fibrillation
2. Upsher-Smith Currently Recruiting People With Epilepsy To Evaluate Investigational Rescue Treatment For Seizure Clusters
3. Cardiometabolic Health Congress Expert Faculty Evaluate the Clinical Implications of Newly FDA-Approved Treatment for Homozygous Familial Hypercholesterolemia
4. Axela Inc. Retains Investment Bank to Evaluate Strategic Opportunities
5. PathoGenetix and FDA to Evaluate Bacterial Identification System for Use in FDA Public Health and Food Safety Efforts
6. MacroGenics Announces Margetuximab (MGAH22) Phase 1 Data Presentation at ASCO; Initiates Phase 2 Clinical Study to Evaluate Activity of Margetuximab in Patients with Metastatic Breast Cancer
7. GenWay Biotech Launches New Cardiovascular Diagnostic Blood Test at American Heart Association Scientific Sessions 2011
8. The Law Firm of Levi & Korsinsky, LLP Launches an Investigation Into Possible Securities Laws Violations by Pacific Biosciences of California, Inc.
9. BioLife Solutions Launches Search Engine Optimized Website and 1,000 Free Samples Offer
10. Ambry Genetics Launches Illumina MiSeq Next-Gen Sequencing Services
11. Neogen Launches Fully Quantitative Lateral Flow Test for DON
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2015)... , May 5, 2015  Blueprint Medicines (NASDAQ: ... its initial public offering of 9,367,708 shares of ... $18.00 per share, including shares of common stock ... of their option to purchase additional shares. The ... Blueprint Medicines were approximately $168.6 million, before underwriting discounts ...
(Date:5/5/2015)... 2015 VetStem Biopharma, proudly announces ... Jeffrey Schaffer, DVM, as Director of Veterinary Professional ... of experience in the veterinary regenerative medicine field ... our veterinarian lead organization”. Dr. Alexis Nahama, ... will be responsible for all technical activities in ...
(Date:5/5/2015)... Israel , May 5, 2015  Tikcro ... Company was approved to continue trading on OTCQB  ... OTCQB Marketplace allows for a continuous ... broker-dealers. Investors can have real-time quotes and market ... The OTCQB Marketplace includes U.S. and ...
(Date:5/5/2015)... NEW YORK , May 5, 2015 /PRNewswire/ ... today announced that Andrew Gengos , President and ... on May 7, 2015. DATE:  Thursday, May ... LINK:  http://VirtualInvestorConferences.com > click the ... will be a live, interactive online event where ...
Breaking Biology Technology:Blueprint Medicines Announces Closing of Initial Public Offering 2Leading Regenerative Veterinary Medicine Company, VetStem Biopharma announces the addition of Dr Jeffrey Schaffer as the Director of Veterinary Professional Services. 2Tikcro Technologies Announces Approval to Continue Trading on OTCQB 2ImmunoCellular Therapeutics to Webcast Live at VirtualInvestorConferences.com on May 7 2
... 11 Schering-Plough,Corporation (NYSE: SGP ) today announced ... of a New Drug Application (NDA) for ZEGERID(R),(omeprazole/sodium bicarbonate) ... a branded over-the-counter (OTC) product to treat frequent,heartburn., ... license agreement with,Santarus, Inc. of San Diego, Calif., which ...
... analysis affordable and accessible to all researchers, ... today that Harvard Medical School and the University ... Program. Each University,purchased access to whole genome human ... Consortium and distributed by Open Biosystems., (Logo: ...
... China,Bionanometer Industries Corporation (Pink Sheets: CBIU), a ... signed an agreement to,establish long-term strategic cooperative ... Guangzhou LGLY Advertising LTD is China,s top ... and is well-known for its core senior ...
Cached Biology Technology:Schering-Plough Announces Filing of U.S. Application for OTC ZEGERID(R) 2Schering-Plough Announces Filing of U.S. Application for OTC ZEGERID(R) 3Open Biosystems' Open Access RNAi Program Adopted by Harvard Medical School and University of North Carolina 2CBIU Signs Agreement with LGLY Advertising LTD 2
(Date:4/13/2015)... , April 13, 2015 ... Research, "Global Biometrics Market Forecast & Opportunities, 2020", the ... CAGR of around 14% till 2020. The biometrics ... large scale implementation and review of biometric management ... of new products with greater efficiency, are resulting ...
(Date:4/10/2015)... 10, 2015 Research and Markets ... "Security Competitive Profiles - NEC" report to ... NEC will continue to supply a range of ... with a company focus on the development of a ... Winning opportunities in the Asia-Pacific ...
(Date:4/8/2015)... N.C. , April 8, 2015  Infinisource, ... solutions and services, and Morpho, a leading supplier ... partnership to produce the market,s most advanced biometrically-enabled ... Infinisource,s iSolved NXG time clock is setting a ... and labor data for the small and mid-size ...
Breaking Biology News(10 mins):Global Biometrics Market to Cross US$ 21 Billion by 2020: TechSci Research 2NEC Security Competitive Profile 2015 2iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 2iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 3
... Deamer began studying the origin of life in the early ... had a major influence on scientific understanding of how life ... (UC Press, June 2011), Deamer presents a personal history of ... and accessible overview of research into life,s beginnings. ...
... of the 2010 Nobel Prize in Chemistry, will be ... Chemistry and Engineering Conference, June 21-23, in Washington, D.C. ... Hilton Hotel, just two blocks north of the White ... around the world, is sponsored by the American Chemical ...
... 2011) New research suggests an effective recovery drink ... Grabbing lowfat chocolate milk after a tough workout helped ... advantage, according to three new studies presented at the ... Journal of Strength and Conditioning Research this ...
Cached Biology News:Biochemist David Deamer explores how life began in new book, 'First Life' 2Nobel Laureate to speak at American Chemical Society green chemistry conference 2New research: Post-exercise recovery advantages of lowfat chocolate milk 2